PM360: COVID-19’s Long-Lasting Impact on Clinical Trials

June 16, 2020

With COVID-19 impacting the conduct of clinical trials, a lot of discussion has been around what changes have allowed trials to continue recruitment. Protocol amendments and the use of technology are just a couple examples of trial aspects that have been drastically impacted by the pandemic, and are expected to see many implemented changes remain.

Read the full article here to learn more about how oncology CROs are uncovering solutions to make trials available to patients now and into the future amid current challenges.

Lost in Translation: Detection of mRNA by Flow Cytometry

By Rubina Pal PhD, Flow Cytometry Scientist

Read more +

Using Flow Cytometry to Characterize Myeloid Derived Suppressor Cells (MDSC)

By Darcey L. Clark, MS DABT, Senior Biotechnology Professional

Read more +

Measuring Innate Immune/Phagocytic Cell Function by Flow Cytometry

By Darcey L. Clark, MS DABT, Senior Biotechnology Professional

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.